1. Home
  2. GBIO vs ATLO Comparison

GBIO vs ATLO Comparison

Compare GBIO & ATLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • ATLO
  • Stock Information
  • Founded
  • GBIO 2016
  • ATLO 1903
  • Country
  • GBIO United States
  • ATLO United States
  • Employees
  • GBIO N/A
  • ATLO N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • ATLO Major Banks
  • Sector
  • GBIO Health Care
  • ATLO Finance
  • Exchange
  • GBIO Nasdaq
  • ATLO Nasdaq
  • Market Cap
  • GBIO 64.8M
  • ATLO 144.8M
  • IPO Year
  • GBIO 2020
  • ATLO N/A
  • Fundamental
  • Price
  • GBIO $0.88
  • ATLO $16.98
  • Analyst Decision
  • GBIO Strong Buy
  • ATLO
  • Analyst Count
  • GBIO 2
  • ATLO 0
  • Target Price
  • GBIO $6.50
  • ATLO N/A
  • AVG Volume (30 Days)
  • GBIO 581.0K
  • ATLO 29.1K
  • Earning Date
  • GBIO 03-05-2025
  • ATLO 01-21-2025
  • Dividend Yield
  • GBIO N/A
  • ATLO 6.00%
  • EPS Growth
  • GBIO N/A
  • ATLO N/A
  • EPS
  • GBIO N/A
  • ATLO 0.98
  • Revenue
  • GBIO $18,582,000.00
  • ATLO $51,071,000.00
  • Revenue This Year
  • GBIO $212.74
  • ATLO N/A
  • Revenue Next Year
  • GBIO N/A
  • ATLO N/A
  • P/E Ratio
  • GBIO N/A
  • ATLO $17.06
  • Revenue Growth
  • GBIO 514.08
  • ATLO N/A
  • 52 Week Low
  • GBIO $0.75
  • ATLO $15.69
  • 52 Week High
  • GBIO $4.65
  • ATLO $22.41
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 28.66
  • ATLO 55.06
  • Support Level
  • GBIO $0.85
  • ATLO $16.04
  • Resistance Level
  • GBIO $1.01
  • ATLO $16.62
  • Average True Range (ATR)
  • GBIO 0.12
  • ATLO 0.40
  • MACD
  • GBIO 0.00
  • ATLO 0.09
  • Stochastic Oscillator
  • GBIO 7.50
  • ATLO 90.44

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About ATLO Ames National Corporation

Ames National Corporation is a United States-based bank holding company. Through its subsidiaries, it provides checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit of payroll and social security checks, and automated/video teller machine access. Its loan portfolio comprises commercial, residential & agricultural real estate loans; agricultural & business operating loans & lines of credit; equipment loans; vehicle loans; personal loans; and mortgage loans. Its operations are conducted in central, north central, and south-central Iowa.

Share on Social Networks: